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Protect the Unprotected: Neonatal Sepsis in
Very-Low-Birth-Weight InfantsIn the past decade, advances in perinatal care have resulted
in the significantly increased survival of preterm infants with
very low birth weight (VLBW). However, prolonged stay in
the Neonatal Intensive Care Unit (NICU) also leads to
increased susceptibility to sepsis. Early- and late-onset
neonatal sepsis remain as the leading causes of mortality
in VLBW infants. In this issue of the Pediatrics and Neona-
tology, Lim et al1 reports that approximately 13% of all VLBW
infants experience one or more episodes of sepsis before
they leave the NICU. In addition to prolonged stays in the
NICU, factors such as an immature immune system, the
fragility of the skin barrier, the frequent use of invasive
procedures, the prolonged use of mechanical ventilation,
and total parental nutrition may account for the higher
incidence and mortality rate of neonatal sepsis that have
been observed in VLBW infants. Clinically, the lack of
specific symptoms, signs, and biomarkers make the early
diagnosis and prompt treatment of sepsis difficult. The
emergence of pathogens with decreased susceptibility to
commonly used antibiotics has also made traditional
empirical antimicrobial treatments inadequate. In the
abovementioned report, nearly 6% of Escherichia coli strains
are reported as resistant to most cephalosporins and 83% of
Staphylococcus aureus strains are reported as resistant to
oxacillin. These results should be used to guide the use of
empirical antibiotics for treating sepsis in VLBW infants.
In the face of these challenges, scientists are actively
evaluating several new strategies with the hope of improving
the survival of VLBW infants with neonatal sepsis. First of all,
rapid and novel diagnostic techniques with higher sensitiv-
ities are being tested with some success.2 For example,
procalcitonin andmannose-binding lectin are probably more
sensitive and specific for detecting the early stages of
bacterial infections than traditional inflammation indicators
such as Erythrocyte Sedimentation Rate (ESR) or C-reactive
protein (CRP). The amplification and detection of nucleic
acids from offending pathogens may also provide additional
useful diagnostic information in a timely fashion.3 The idea
of applying proteomics-based techniques for detecting1875-9572/$36 Copyright ª 2012, Taiwan Pediatric Association. Publish
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patterns also show promising results. Second, in addition to
appropriate antimicrobial therapies, nonmedicinal inter-
ventions are also important. It has been reported that the
majority of sepsis is late-onset and caused by Gram-positive
organisms (60.6%), among which 86.5% are coagulase-
negative staphylococci. Group B Streptococcus (GBS) is
extremely rare in VLBW infants. These results are in accor-
dance with earlier reports,4 and they suggest that the inva-
sion of skin flora is themajor route of infection formost cases
of late-onset sepsis in VLBW infants. The importance of strict
obedience to aseptic procedures, especially good hand
hygiene, cannot be overemphasized.5 The prompt removal
of indwelling catheters is also an important part of the
integrated management of sepsis in VLBW infants. Despite
the use of appropriate antimicrobial therapies, the
morbidity and mortality of sepsis in VLBW infants remain
high. The use of certain adjuvant therapies for treating
neonatal sepsis has been repeatedly proposed. Since trans-
placental transfer of maternal protective antibodies does
not occur until week 32 of gestation, the infusion of intra-
venous immunoglobulins (IVIG) may help to control sepsis in
this population. However, a recently reported large
randomized trial involving 3493 cases concluded that
therapy with IVIG has no effect on the clinical outcomes of
suspected or proven neonatal sepsis.6 Studies on other
adjuvant therapies, such as colony-stimulating factors,
pathogen-specific protective antibodies, probiotics, gluta-
mine supplementation, and lactoferrin, have been tested
with mixed results. It is hoped that investigators will finally
find adjuvant therapies that are beneficial for treating VLBW
infants with sepsis in the future.
In terms of prevention, maternal immunization is an
attractive strategy. Some early-stage human studies on
maternal immunization with GBS vaccines have shown
promising results.7 However, vaccines against other bacteria
are desirable for use in VLBW infants because GBS infection
is infrequent in this population. The safety of vaccination
during pregnancy is also a concern, especially when theed by Elsevier Taiwan LLC. All rights reserved.
218 Editorialvaccines need to be administered during early pregnancy in
order to provide timely protection for VLBW infants.
Because they leave their mothers’ immunological shield
unprepared for the outside world, VLBW infants require
special protection. Prompt and appropriate antimicrobial
therapy remains the key to the successful treatment of
sepsis in these infants. To achieve this goal, maintaining
a higher index of suspicion and continuously monitoring
local epidemiological factors are crucial. In addition,
developing novel therapeutic and preventive strategies are
also highly desirable.
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